TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today)
TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today)
EntreMed Inc. managed to resolve ongoing litigation, bring in the necessary cash to fund operations for some time and help alleviate issues surrounding a potential Nasdaq delisting through one move - the signing of a deal valued at about $27 million with Celgene Corp. for EntreMed's thalidomide analogue program. (BioWorld Today)
EntreMed Inc. managed to resolve ongoing litigation, bring in the necessary cash to fund operations for some time and help alleviate issues surrounding a potential Nasdaq delisting through one move - the signing of a deal valued at about $27 million with Celgene Corp. for EntreMed's thalidomide analogue program. (BioWorld Today)
